CVS Health Q2 revenue beats estimates, outlook raised
CVS Health Q2 revenue beats estimates, outlook raised
Overview
U.S. health solutions provider's Q2 revenue rose 7.3% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat consensus, driven by improved Health Care Benefits segment margin recovery
Company raised full-year 2026 guidance for EPS and cash flow from operations
Outlook
CVS raises 2026 GAAP diluted EPS guidance to $6.84-$7.04 from $6.24-$6.44
Company lifts 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50
CVS increases 2026 cash flow from operations guidance to at least $11.5 bln from at least $9.5 bln
Result Drivers
HEALTH CARE BENEFITS MARGIN RECOVERY - Adjusted operating income rose sharply in the Health Care Benefits segment, driven by improved performance in the Government business and the absence of a prior-year premium deficiency reserve
PHARMACY DRUG MIX AND BRAND INFLATION - Health Services segment revenue grew due to pharmacy drug mix and brand inflation, partially offset by pharmacy client price improvements
RITE AID ASSET ACQUISITIONS - Increased prescription volume in Pharmacy & Consumer Wellness segment was supported by contributions from Rite Aid asset acquisitions and brand inflation, though offset by regulatory-related price reductions and reimbursement pressure
Company press release: ID:nPnbvjs38a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $106.10 bln | $100.11 bln (19 Analysts) |
Q2 Adjusted EPS | Beat | $2.58 | $1.85 (23 Analysts) |
Q2 EPS |
| $2.31 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for CVS Health Corporation is $113.00, about 8.2% above its August 4 closing price of $104.42
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago
Reuters Recommended Reads
Aug 5 - CVS raises annual profit forecast on improved drug revenues
Aug 4 - Weis Markets Q2 profit falls as pharmacy pricing headwinds weigh
Aug 4 - Dialysis provider DaVita's Q2 results beat estimates, aided by higher average rates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on CVS Health
See all newsHealth Rounds: GLP-1 drugs tied to heart improvements in patients with obesity and heart failure
US health insurers fall for third day on CMS audit proposal, Medicare-for-All concerns
Health insurers extend decline on proposed new rule to curb fraud
Health insurers extend decline on proposed new rule to curb fraud
UnitedHealthcare to expand program paying pharmacists for medical services